Jacobs Levy Equity Management
PTLA

Jacobs Levy Equity Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Jacobs Levy Equity Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,560
Closed -$190K – 1147
2020
Q2 		$190K Sell
10,560
-257,642
-96% -$3.58M ﹤0.01% 960
2020
Q1 		$1.91M Buy
+268,202
New +$3.35M 0.02% 483
2017
Q4 		– Sell
-6,950
Closed -$376K – 1101
2017
Q3 		$376K Sell
6,950
-8,260
-54% -$485K 0.01% 749
2017
Q2 		$854K Buy
+15,210
New +$609K 0.02% 594
2016
Q4 		– Sell
-14,200
Closed -$322K – 1098
2016
Q3 		$322K Sell
14,200
-123,630
-90% -$2.9M 0.01% 795
2016
Q2 		$3.25M Buy
137,830
+15,150
+12% +$374K 0.07% 333
2016
Q1 		$2.5M Buy
+122,680
New +$3.89M 0.05% 358

Jacobs Levy Equity Management's PTLA Position: Q3 2020 in Review

Jacobs Levy Equity Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 10,560 shares — an estimated $190K sold.

Jacobs Levy Equity Management first reported a position in PTLA in Q1 2016 and held it in 7 quarters. The position peaked at $3.25M in Q2 2016. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Jacobs Levy Equity Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 10,560 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $190K.
  • Jacobs Levy Equity Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2016 and held it in 7 quarters.
  • Jacobs Levy Equity Management's Portola Pharmaceuticals, Inc. position peaked at $3.25M in Q2 2016.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2020, filed 16 Nov 2020.